Stryker Corporation (NYSE:SYK) Receives $380.40 Consensus Target Price from Brokerages

Stryker Corporation (NYSE:SYK) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-three ratings firms that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $378.1250.

A number of research analysts recently issued reports on the company. Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Argus set a $370.00 price target on shares of Stryker in a report on Thursday, July 9th. Wells Fargo & Company lowered their price target on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating for the company in a research report on Wednesday, September 9th. Raymond James Financial set a $370.00 price objective on shares of Stryker in a report on Friday, July 31st. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $317.00 price objective on shares of Stryker in a research report on Wednesday, September 9th.

Stryker Stock Performance

Shares of SYK opened at $273.69 on Tuesday. The stock has a market capitalization of $104.98 billion, a PE ratio of 28.36, a price-to-earnings-growth ratio of 1.74 and a beta of 0.76. The business’s fifty day moving average price is $318.75 and its 200 day moving average price is $321.61. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. Stryker has a 12-month low of $267.00 and a 12-month high of $392.55.

Stryker (NYSE:SYK) last released its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same quarter in the previous year, the firm earned $3.13 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts forecast that Stryker will post 15 EPS for the current year.

Stryker Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.3%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Insider Buying and Selling at Stryker

In related news, insider Dylan Crotty sold 441 shares of the stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the transaction, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Gables Capital Management Inc. acquired a new stake in Stryker in the second quarter worth about $25,000. Kilter Group LLC acquired a new position in Stryker during the 2nd quarter valued at about $25,000. Highland Investment Advisors LLC acquired a new position in Stryker during the 2nd quarter valued at about $25,000. Cornerstone Financial Management LLC raised its position in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock worth $25,000 after buying an additional 31 shares in the last quarter. Finally, Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker in the 4th quarter worth approximately $26,000. Institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.